Is Pharmaniaga (PHARMA) fundamentally undervalued?

On trailing metrics it screens cheap (e.g., low P/E and P/S), but forward metrics and execution risks (liquidity, net debt, PN17 overhang) must be considered. Valuation may reflect these risks.

What are the key price levels for PHARMA?

Near-term support is around RM 0.18; resistance near RM 0.22 and RM 0.26. A sustained move above the 200-DMA (~RM 0.26) would help confirm a broader trend reversal.

What news could move PHARMA’s price?

Updates on PN17 regularisation, tender outcomes (e.g., insulin supply), quarterly earnings, and debt/cash flow milestones are primary catalysts that can move the share price.

What is the 12-month price outlook for PHARMA?

Street consensus points to ~RM 0.15 over 12 months, implying potential downside from ~RM 0.215. Outcomes will depend on execution of restructuring and tender wins.

How long should I hold PHARMA?

Short-term (1–3 months): range trade between RM 0.18–0.22. Up to 12 months: hold only if catalysts progress; otherwise reduce. 12+ months: speculative hold contingent on turnaround execution.

KLSE: PHARMA : Fundamentals, Technicals, News & Price Outlook

Pharmaniaga Berhad (KLSE: PHARMA) — Fundamentals, Technicals, News & Price Outlook

Last updated: 10 Sep 2025 • Currency: MYR • Sector: Healthcare (Pharmaceuticals)

Last Close (approx.)

RM 0.215

Market Cap (approx.)

~ RM 1.4B

TTM Revenue (approx.)

~ RM 3.9B

Trailing P/E

~ 2.3x

Forward P/E

~ 30x

Net Debt (approx.)

~ RM 1.0B

1) Fundamental Analysis

Valuation

Historically low trailing P/E (~2–3x) vs far higher forward P/E (~30x) → earnings base likely normalising; watch revision risk.
P/S ~0.3–0.4x; EV/EBITDA mid-single-digits → screens “cheap” on some metrics but reflects risk.

Profitability & Cash

Margins modest (low-teens gross; mid-single operating). Free cash flow positive on recent TTM.
Interest coverage adequate but sensitive to borrowing costs.

Balance Sheet

Liquidity tight (current ratio <1). Net debt ~RM1B → deleveraging is a key watch-item.
Previously flagged going-concern/PN17 context; management pursuing regularisation & capital actions.

Takeaway: Value metrics attractive but tied to execution on turnaround/liquidity.

2) Technical Analysis (snapshot)

Trend: Volatile recovery; price hovering between 50-DMA (~RM 0.18) and 200-DMA (~RM 0.26).
Momentum: RSI ~55–60 (neutral-positive); not overbought.
Key levels: Support ~RM 0.18; resistance ~RM 0.22 then ~RM 0.26.
Risk: Elevated volatility vs market; news-driven swings possible.

Indicator	Reading	View
50-DMA	~ 0.18	Above support → constructive if held
200-DMA	~ 0.26	Major hurdle for trend reversal
RSI (14)	~ 59	Neutral–positive
Volume	Spiky	News-sensitive

3) News & Catalysts (high-level)

PN17 regularisation: Ongoing steps (rights issue/private placement) aimed at exiting PN17 in stages.
Tender pipeline: Insulin supply & related concessions remain potential revenue drivers.
Earnings prints: Recent quarters showed profit improvement YoY off a low base; sensitivity to concession volumes.
Shareholder flows: Institutional participation reported; monitor substantial shareholder changes.

Catalyst map: PN17 updatesTender resultsQuarterly earningsDebt/CF trends

4) Price Prediction & Suggested Hold Duration

Street 12-mo target (consensus): ~RM 0.15 (implies downside from ~RM 0.215).
Short-term model snapshots (≈2 weeks): ~RM 0.18–0.20 range bias in some quantitative feeds.

Horizon	Target / Range	Strategy
1–3 months	Range trade RM 0.18–0.22	Hold/trade around support & resistance; cut below 0.18, scale out near 0.22.
Up to 12 months	Street target ~0.15 (risk)	Maintain only if PN17 exit/tenders show progress; otherwise reduce.
12+ months	Speculative upside if turnaround executes	High-beta, catalyst-driven; position sizing is key.

Risk controls: preset stop (~0.18), take-profit (~0.22/0.26), reassess on catalyst outcomes.

5) Quick Pros & Cons

Pros: Low headline valuation; improving prints off low base; potential tender wins.
Cons: Tight liquidity; elevated net debt; PN17/going-concern overhang; forecast uncertainty.

Disclaimer

This content is for information only and is not investment advice. Figures are approximate and may change. Always verify with official filings and your broker’s data before trading.